Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Unit price / market price
-
$1.83
-
Total 13F principal
-
$243,307,000
-
Principal change
-
+$1,850,000
-
Total reported value
-
$444,694,000
-
Number of holders
-
23
-
Value change
-
+$3,644,154
-
Number of buys
-
8
-
Number of sells
-
7
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q4 2017
As of 31 Dec 2017 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 had 23 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $243,307,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included CITADEL ADVISORS LLC, CQS Cayman LP, Polygon Management Ltd., HIGHBRIDGE CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Allianz Asset Management GmbH, WELLS FARGO & COMPANY/MN, ANGELO GORDON & CO., L.P., CSS LLC/IL, and CALAMOS ADVISORS LLC.
This table shows 23 bond principal holders of the security as of 31 Dec 2017.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.